The development of Burkholderia vaccines and therapeutics is quite complicated in nature. Combating against this type of infection involves having a thorough understanding of the disease, conducting strategic research, and carrying out multiple preclinical operations. All of which we are proficient in carrying out and would assist you with.
Introduction to Burkholderia Infection
Infections with Burkholderia are caused by a collection of bacteria falling in the class of Gram-negative bacteria within the genus Burkholderia. These bacteria are distinguished by their metabolic and environmental versatility which makes some of the species dangerous to humans and animals. From the medical point of view, the most dangerous species are Burkholderia mallei which causes glanders and Burkholderia pseudomallei which is responsible for melioidosis. The Burkholderia cepacia complex (Bcc), on the other hand, has been reported to cause respiratory infections in people suffering from cystic fibrosis.
Fig. 1 Vaccine candidate evaluated as melioidosis vaccine. (Yagupsky P., et al., 2019)
Vaccine Development for Burkholderia Infection
Inactivated Whole-Cell Vaccines
These vaccines rely on inactivated bacteria in order to elicit strong humoral immuneresponses. Chemically-inactivated or heat-inactivated vaccines have demonstrated various possibilities within pre-clinical models, introducing responsive capabilities for challenges against virulent strains.
Live Attenuated Vaccines
Attenuated vaccines employ weakened life forms to instigate robust and enduring immune responses. Such action has led to the development of mutants that are deficient in critical pathways and demonstrate strong protective effects in animal models.
Subunit and Glycoconjugate Vaccines
The starting point of these vaccines is on specific antigens which can elicit a protective immune response. Against the backdrop of Burkholderia species, glycoconjugate vaccines that link polysaccharide antigens to protein carriers have also been shown to promote immune response.
DNA and Viral Vector-Based Vaccines
DNA vaccines and viral vector-based vaccines are modern techniques which offer genetic material that codes for protective antigens and is able to trigger immune responses of great magnitude. These novel vaccine platforms have shown promise in protecting individuals against Burkholderia infections.
Therapeutics Development for Burkholderia Infection
The procedural outline for the development of Burkholderia infection therapies includes synthesis and/or the search for novel antibacterial drugs that specifically target these infection inducing bacteria. Given the fact that Burkholderia infections are highly resistant , generation of new therapeutics is singnificantly critical and indeed a paramount consideration.
- β-Lactam Antibiotics: The need for developing third and fourth generation beta lactam antibiotic such as ceftazidime is critical to the therapeutic of Burkholderia infections.
- Fluoroquinolones and Trimethoprim: These are other therapy modalities that are enzyme specific and target some pathways in the bacteria.
For further information on the various therapy development services we offer, please click on the link below
Our Services
Our firm has devoted considerable skills to evolving new solutions for the therapeutics of Burkholderia infections, and we are not just starting. The services for the development of therapies we offer revolve on the discovery of new agents or optimization of the existing ones to increase their activity towards Burkholderia species.
Disease Models
- Burkholderia mallei Infection Models
- Burkholderia pseudomallei Infection Models
- Burkholderia cepacia complex (Bcc) Infection Models
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
Our preclinical research services aid in the assessment of vaccine and therapy candidate safety and efficiency. If you are interested in our services and would like more information or a quote, please don't hesitate to contact us.
References
- Yagupsky Pablo, Pilar Morata, and Juan D. Colmenero. "Laboratory diagnosis of human brucellosis." Clinical microbiology reviews 33.1 (2019): 10-1128.
- Lalsiamthara, Jonathan, and John Hwa Lee. "Development and trial of vaccines against Brucella." Journal of Veterinary Science 18.S1 (2017): 281-290.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
